81 Results for "

GSK3α

" in MedChemExpress (MCE) Product Catalog:
Products (81)

81 Results for "GSK3α" in MCE Product Catalog:

315
315 Publications Verification
Cat. No.: HY-10182
CAS No.: 252917-06-9
Purity:  99.43%
Synonyms: CHIR-99021; CT99021
Research Areas:  

Metabolic Disease Cancer

Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy [3].
loading...
    loading...
315
315 Publications Verification
Cat. No.: HY-10182B
CAS No.: 1782235-14-6
Purity:  99.07%
Synonyms: CHIR-99021 trihydrochloride; CT99021 trihydrochloride
Research Areas:  

Cancer

Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy [3].
loading...
    loading...
315
315 Publications Verification
Cat. No.: HY-10182A
CAS No.: 1797989-42-4
Purity:  99.93%
Synonyms: CHIR-99021 monohydrochloride; CT99021 monohydrochloride
Research Areas:  

Cancer

Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy [3].
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-12012
CAS No.: 280744-09-4
Purity:  99.37%
Target:  

GSK-3 Autophagy

Research Areas:  

Neurological Disease Cancer

SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC50s of 34.3 nM for both GSK-3α and GSK-3β.
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-16294
CAS No.: 603288-22-8
Target:  

GSK-3

Research Areas:  

Cancer

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-10580
CAS No.: 667463-62-9
Purity:  99.31%
Synonyms: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052
Target:  

GSK-3 CDK Apoptosis

Research Areas:  

Cancer

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-13076
CAS No.: 252935-94-7
Purity:  98.44%
Target:  

GSK-3

Research Areas:  

Metabolic Disease

CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-15761
CAS No.: 486424-20-8
Purity:  98.42%
Target:  

GSK-3

Research Areas:  

Neurological Disease

AZD2858 is a potent, orally active GSK-3 inhibitor, with IC50s of 0.9 and 5 nM for GSK-3α and GSK-3β, respectively, used in the research of fracture healing.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15438
CAS No.: 264218-23-7
Purity:  99.46%
Target:  

GSK-3 Apoptosis

Research Areas:  

Metabolic Disease

SB 415286 is a potent and selective cell permeable inhibitor of GSK-3α, with an IC50 of 77.5 nM, and a Ki of 30.75 nM; SB 415286 is equally effective at inhibiting human GSK-3α and GSK-3β.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13862
CAS No.: 612487-72-6
Purity:  99.46%
Target:  

GSK-3

Research Areas:  

Neurological Disease

AZD1080 is a potent and selective GSK3 inhibitor. AZD1080 inhibits recombinant human GSK3α and GSK3β with pKi (IC50) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-149143
CAS No.: 2765255-93-2
Purity:  98.82%
Target:  

TRP Channel

Research Areas:  

Inflammation/Immunology

JNJ-28583113 is an TRPM2 antagonist with brain permeability. JNJ-28583113 inhibits TRPM2 blocked phosphorylation of GSK3α and β subunits. JNJ-28583113 protects cells from oxidative stress induced cell death. JNJ-28583113 also suppresses cytokine release in response to pro-inflammatory stimuli in microglia .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N1472
CAS No.: 88182-33-6
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways [3] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10182G
CAS No.: 252917-06-9
Synonyms: CHIR-99021 (GMP); CT99021 (GMP)
Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-124607B
CAS No.: 2056262-07-6
Purity:  98.21%
Target:  

GSK-3

BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15356
CAS No.: 667463-85-6
Purity:  ≥98.0%
Synonyms: BIA
BIO-acetoxime (BIA) is a potent and selective GSK-3 inhibitor, with IC50s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-116830
CAS No.: 2056261-41-5
Purity:  99.86%
Target:  

GSK-3

Research Areas:  

Cancer

BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108359
CAS No.: 237430-03-4
Purity:  99.85%
Synonyms: 9-Nitropaullone; NSC 705701
Target:  

CDK GSK-3 Apoptosis

Research Areas:  

Cancer

Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC50s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC50s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders . Alsterpaullone induces apoptosis in leukemia cell line .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119940
CAS No.: 2237942-08-2
Purity:  98.89%
Synonyms: (rel)-MC180295
Target:  

CDK

Research Areas:  

Cancer

MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .
loading...
    loading...
Cat. No.: HY-153166
CAS No.: 2721998-87-2
Purity:  98.4%
Target:  

PROTACs GSK-3 Tau Protein

Research Areas:  

Neurological Disease

PT-65 is a GSK3α and GSK3β PROTAC degrader with DC50 values of 28.3 nM and 34.2 nM, respectively. PT-65 inhibits excessive tau phosphorylation mediated by GSK3β, Aβ and Okadaic acid (HY-N6785). PT-65 is applicable for the research of Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-107531
CAS No.: 1384424-80-9
Purity:  99.87%
Target:  

GSK-3

Research Areas:  

Neurological Disease Cancer

A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .
loading...
    loading...